The international Cell & Gene Therapy World conference gather nearly 1,300 industry professionals from more than 30 countries.
Corbeil-Essonnes, France, January 26, 2017 - YposKesi, the first French pharmaceutical company to develop and manufacture gene and cell therapy products for rare diseases, presented its latest advances in viral vector production processes (AAVs) at the Cell & Gene Therapy World event, « Meet the future of cell & gene therapy » which took place from 22 to 25 January 2018 in Miami, USA.
The international Cell & Gene Therapy World conference, one of the most important event in the sector, gather nearly 1,300 industry professionals from more than 30 countries.
The launch of 3 products on the market in 2017 represents a key step in the field of gene therapy and more than twenty registrations are expected in the next 5 years. The constant increase in the number of products under development will require sufficient production capacity and efficient production processes.
As part of his presentation entitled “Improved Manufacturing Platform for AAV Manufacturing”, Alain Lamproye, CEO of Yposkesi, highlighted the new technological developments made jointly with Généthon. These developments have led to a very significant increase of AAV processes productivity, results of the significant R&D efforts made by Yposkesi.
Viral vectors production for a gene therapy use presents considerable challenges, the improvement of production yields being one of the main ones. This increase of productivity is essential to meet not only the future needs of the industry, but also to drastically reduce production costs.
“As a European leader of gene and cell therapy drugs production for rare diseases, continuous innovation is a major challenge in our development strategy. The optimization of viral vector production capabilities and processes is essential to enable our partners to make tomorrow’s treatments accessible. We are proud of our progress, and our experts continue to work every day to offer ever more innovative and economical processes”, said Alain Lamproye, CEO of Yposkesi.
ABOUT YPOSKESI
Yposkesi is a European industrial leader for Gene and Cell Therapy with the mission of developing, manufacturing and making available Gene and Cell therapy treatments to patients affected with rare diseases. It was launched in November 2016 in Evry (France) by the patient organization AFM-Téléthon with the support of the SPI fund from the French Public Investment Bank (BPI France), with a total investment of €121M. It is made up of 150 experts in bioproduction and has a first production building covering 5'000 m2. The broad expertise of Yposkesi covers the production of viral vectors for gene therapy (Lentivirus & AAV), transduction of hematopoietic stem cells and production of human pluripotent stem cells, with also significant efforts in developing innovative process for large-scale cost-effective manufacturing process of these highly complex ATMPs. The plans are to extend the production capacity with two additional buildings for a total of 13'000 m2 by 2021.
For more information, please visit our website at: www.yposkesi.com
CONTACTS
| Press Relations - ALIZE RP |
| Caroline Carmagnol et Aurore Gangloff |
| Mail : yposkesi@alizerp.com |
| Tél. : 01 44 54 36 66 |
